Scientific work

Doç. Dr. Oğuzcan Kınıkoğlu

70 publications. The source of the information is stated next to each publication.

Back to profile

  1. Real-World Outcomes of Neoadjuvant Dual Blockade in HER2-Positive Breast Cancer: The Role of Tumor Biology and pCR

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15062217 PMID 41899145 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  2. Prognostic value of PSA Kinetic Ratio in high-volume mCSPC patients treated with abiraterone or enzalutamide: a single-center retrospective study

    BMC Cancer, 2026

    DOI 10.1186/s12885-026-16037-8 PMID 41987096 Open-access full textSource: OpenAlex

  3. Association Between Time to PSA Nadir, Radiologic Progression, and PSA Progression in mHSPC Patients Treated with Abiraterone or Enzalutamide

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15010386 PMID 41517635 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  4. Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma

    Journal of Cancer Research and Clinical Oncology, 2026

    DOI 10.1007/s00432-025-06411-7 PMID 41504775 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  5. Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk–Stratified Analysis

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15051853 PMID 41827267 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  6. Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62010099 PMID 41597386 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  7. FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval

    Cancers, 2026

    DOI 10.3390/cancers18182987 PMID 42794953 Open-access full textSource: OpenAlex

  8. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026

    DOI 10.1007/s12094-026-04228-5 PMID 41670816 Source: Europe PMC

  9. Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

    Cancers, 2026

    DOI 10.3390/cancers18142302 PMID 42512369 Open-access full textSource: ORCID

  10. Clinicopathologic Determinants of Overall Survival in Adrenocortical Carcinoma: A SEER-Based Population Study

    Cancers, 2026

    DOI 10.3390/cancers18071103 PMID 41976326 Open-access full textSource: ORCID

  11. Cytotoxic effect of famotidine in breast adenocarcinoma cells line

    Northern Clinics of Istanbul, 2026

    DOI 10.14744/nci.2026.55899 PMID 41940059 Open-access full textSource: OpenAlex

  12. 486P Machine learning–based prediction of nivolumab response using systemic inflammatory biomarkers in advanced NSCLC: A real-world study

    ESMO Open, 2026

    DOI 10.1016/j.esmoop.2026.106800 Open-access full textSource: OpenAlex

  13. 105P HER2 amplification drives resistance to anti-EGFR therapy in RAS/BRAF wild-type metastatic colorectal cancer: A real-world study

    Annals of Oncology, 2026

    DOI 10.1016/j.annonc.2026.05.106 Open-access full textSource: OpenAlex

  14. Real-life data on adjuvant trastuzumab emtansine treatment in early-stage HER2-positive breast cancer: a Turkish Oncology Group study

    Anti-Cancer Drugs, 2025

    DOI 10.1097/cad.0000000000001717 PMID 40162996 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  15. The Association of Khorana Risk Score with Venous Thromboembolism and Overall Survival in Patients with Metastatic Gastric Cancer

    Medicina, 2025

    DOI 10.3390/medicina61061075 PMID 40572762 6 citations (Europe PMC) Open-access full textSource: OpenAlex

  16. Real‐world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple‐negative breast cancer: A multicenter study by the Turkish Oncology Group

    International Journal of Cancer, 2025

    DOI 10.1002/ijc.70213 PMID 41147655 3 citations (Europe PMC) Source: OpenAlex

  17. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study

    Medicina, 2025

    DOI 10.3390/medicina61030490 PMID 40142301 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  18. Kanserde Takip

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716 Open-access full textSource: OpenAlex

  19. Tumor-infiltrating lymphocytes as predictive biomarkers in neoadjuvant treatment of HER2-positive breast cancer

    The Oncologist, 2025

    DOI 10.1093/oncolo/oyaf054 PMID 40271640 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  20. Evaluating the Performance of ChatGPT-4o Oncology Expert in Comparison to Standard Medical Oncology Knowledge: A Focus on Treatment-Related Clinical Questions

    Cureus, 2025

    DOI 10.7759/cureus.78076 PMID 39872919 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  21. Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14197103 PMID 41096183 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  22. Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study

    Journal of Personalized Medicine, 2025

    DOI 10.3390/jpm16010008 PMID 41590501 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  23. The Effect of the Clinical-Pathological CPS+EG Staging System on Survival Outcomes in Patients with HER2-Positive Breast Cancer Receiving Neoadjuvant Treatment: A Retrospective Study

    Medicina, 2025

    DOI 10.3390/medicina61101813 PMID 41155800 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  24. Comparison of paclitaxel and docetaxel in dual HER2 blockade: efficacy and safety in neoadjuvant treatment of HER2-positive breast cancer

    Breast Cancer Research and Treatment, 2025

    DOI 10.1007/s10549-025-07694-7 PMID 40214840 2 citations (Europe PMC) Source: OpenAlex

  25. Impact of HER2 Status Assessed by Immunohistochemistry on Treatment Response in Patients with Metastatic Breast Cancer Receiving Trastuzumab Emtansine

    Medicina, 2025

    DOI 10.3390/medicina61050819 PMID 40428777 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  26. Effects of Metformin on Survival and Toxicity in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

    Medicina, 2025

    DOI 10.3390/medicina61071161 PMID 40731791 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  27. The impact of carboplatin on pathologic complete response and survival based on HER2 low and HER2 zero status in triple negative breast cancer patients receiving neoadjuvant chemotherapy: a multicenter real-world analysis

    BMC Cancer, 2025

    DOI 10.1186/s12885-025-14252-3 PMID 40329228 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  28. Impact of Age and Menopausal Status on T-DM1 (Ado-Trastuzumab Emtansine) Treatment Outcomes in HER2-Positive Breast Cancer

    Pharmaceuticals, 2025

    DOI 10.3390/ph18060931 PMID 40573326 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  29. Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

    Current Oncology, 2025

    DOI 10.3390/curroncol32090503 PMID 41002573 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  30. Impact of Metastasectomy on Survival Outcomes in Colorectal Cancer: A Single Center Retrospective Study

    Acta haematologica oncologica Turcica., 2025

    DOI 10.4274/ahot.galenos.2025.2025-1-1 Open-access full textSource: OpenAlex

  31. Very Favorable vs. Favorable Risk Groups in Metastatic Renal Cell Carcinoma: A Step Toward Personalized Treatment

    Cancers, 2025

    DOI 10.3390/cancers17071076 PMID 40227569 Open-access full textSource: OpenAlex

  32. Effect of Family and Personal Medical History on Treatment Outcomes of Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)

    Healthcare, 2025

    DOI 10.3390/healthcare13151810 PMID 40805843 Open-access full textSource: OpenAlex

  33. Association Between Prognostic Nutritional Index and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

    Cerrahpasa Medical Journal, 2025

    DOI 10.5152/cjm.2025.25030 Open-access full textSource: OpenAlex

  34. The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

    Journal of Chemotherapy, 2025

    DOI 10.1080/1120009x.2025.2601938 PMID 41414901 Source: OpenAlex

  35. The Effect of Concomitant Metformin Use on Progression-Free and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab

    2025

    DOI 10.20944/preprints202506.0074.v1 Open-access full textSource: ORCID

  36. Kanser Hastalarında Uyku Bozuklukları

    Akademisyen Kitabevi eBooks, 2025

    DOI 10.37609/akya.3716.c6102 Source: ORCID

  37. The Role of Pre-Treatment Inflammatory Biomarkers in Predicting Tumor Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer

    Medicina, 2025

    DOI 10.3390/medicina61050865 PMID 40428824 4 citations (Europe PMC) Open-access full textSource: ORCID

  38. Efficacy and Safety of CDK4/6 Inhibitor Therapy in Patients Aged 70 and Older with Metastatic Breast Cancer: A Retrospective Single-Center Analysis

    Southern Clinics of Istanbul Eurasia, 2025

    DOI 10.14744/scie.2025.20092 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  39. Evaluating health and functional impairments in axial spondyloarthritis: A comprehensive analysis using the ASAS Health Index and Environmental Factors

    Northern Clinics of Istanbul, 2025

    DOI 10.14744/nci.2024.04307 PMID 40838230 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  40. Efficacy and Safety of the Topotecan–Cyclophosphamide Regimen in Adult Metastatic Ewing Sarcoma: A Large, Multicenter, Real-World Study

    Cancers, 2025

    DOI 10.3390/cancers17030550 PMID 39941915 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  41. The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study

    Figshare, 2025

    DOI 10.6084/m9.figshare.30919274 Open-access full textSource: OpenAlex

  42. MANAGEMENT OF ONCOLOGIC DISEASES IN PATIENTS WITH MULTIMORBIDITY

    Turkiye Klinikleri eBooks, 2025

    DOI 10.5336/978-625-395-749-0_p139 Source: OpenAlex

  43. MANAGEMENT OF METASTATIC BREAST CANCER

    Turkiye Klinikleri eBooks, 2025

    DOI 10.5336/978-625-395-705-6_p145 Source: OpenAlex

  44. Kanser Hastalarının Başvurduğu Geleneksel ve Tamamlayıcı Tedaviler - Tıbbi Onkolog Gözü ile Bakış ve Onkolojik İlaçlarla Etkileşim

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2380 Open-access full textSource: OpenAlex

  45. The role of laboratory indices on treatment response and survival in breast cancer receiving neoadjuvant chemotherapy

    Scientific Reports, 2024

    DOI 10.1038/s41598-024-63096-7 PMID 38802494 21 citations (Europe PMC) Open-access full textSource: OpenAlex

  46. Prognostic Impact and Clinical Features of Spread through Air Spaces in Operated Lung Cancer: Real-World Analysis

    Medicina, 2024

    DOI 10.3390/medicina60081374 PMID 39202654 10 citations (Europe PMC) Open-access full textSource: OpenAlex

  47. Neoadjuvant Chemotherapy and Pathologic Complete Response in HR+/HER2− Breast Cancer: Impact of Tumor Ki67 and ER Status

    Chemotherapy, 2024

    DOI 10.1159/000537874 PMID 38368871 5 citations (Europe PMC) Source: OpenAlex

  48. A Novel Prognostic Indicator for Immunotherapy Response: Lymphocyte-to-Albumin (LA) Ratio Predicts Survival in Metastatic NSCLC Patients

    Cancers, 2024

    DOI 10.3390/cancers16142512 PMID 39061152 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  49. Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older

    Journal of Clinical Medicine, 2024

    DOI 10.3390/jcm13206263 PMID 39458213 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  50. Does Adjuvant Chemotherapy Benefit Patients with T4 N0 Colon Cancer?

    Medicina, 2024

    DOI 10.3390/medicina60081372 PMID 39202652 3 citations (Europe PMC) Open-access full textSource: OpenAlex